The data: US health insurers slashed prior authorizations by 11% in the past year, according to health plan trade group AHIP.

• For context, prior authorization is a cost-control process used by health plans requiring clinicians to obtain approval before delivering a service or medication to ensure it’s medically necessary.
• 6.5 million fewer prior authorizations were realized across a range of medical services.
• Pre-treatment/service reviews were reduced by 15% in Medicare Advantage (MA) plans, which is notable since prior authorizations are much more prevalent in MA than in traditional Medicare.

How we got here: Last year, insurers pledged to slash prior authorizations and speed up approvals. While they claim these hurdles curb waste, critics see a profit-driven tactic to second-guess doctors and deny care. These administrative roadblocks force physicians to justify treatments and services, which can result in denials that prioritize the bottom line over the patient.

Why it matters: Consumers and doctors see prior authorizations as bottlenecks that can meaningfully hinder patient care.

• Beyond costs, prior authorization is the top barrier to care for insured US adults, with one-third calling it a major burden, according to a February KFF poll.
• Roughly 70% of people whose care or treatment changed due to prior authorization said it negatively impacted their health.
• 82% of clinicians say prior authorization sometimes leads patients to abandon treatment, according to AMA data—likely driven by time wasted on getting approvals and high out-of-pocket costs when coverage is denied.

Implications for health insurers and healthcare providers: An 11% drop in prior authorizations is a hollow metric. It fails to identify which treatments are affected, whether physician workloads have actually decreased, or if high-needs patients still face life-altering delays. Regulators will likely ignore these marginal "improvements" as they finalize rules for even faster reviews. Despite industry claims that denials are rare, congressional pressure and high-profile coverage of denied care will keep insurer business practices under a microscope.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.